Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* laboratory confirmed positive test for SARS-CoV-2~* admitted to ICU because of critical illness due to covid-19~Exclusion Criteria:~* patients with treatment for thromboembolic complications at arrival to the ICU~* short ICU length of stay defined as discharged the same or the following day as ICU admission

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- thrombose prophylaxis (Type: None): The dose used to prevent thromboembolic complication in critically ill
- double thrombose prophylaxis (Type: None): Double the dose used to prevent thromboembolic complication in critically ill
- full dose anticoagulant (Type: None): Dose used to treat thromboembolic event

Based on this trial design, predict the completion outcome and termination type (if applicable).